HEPATOPROTECTIVE EFFECT OF OXYRESVERATROL IN ISONIAZID INDUCED HEPATOTOXICITY IN EXPERIMENTAL MICE MODEL.

Abstract

Introduction: The liver is the main organ for maintaining the body’s metabolic homeostasis. The prescription for tuberculosis (TB) diagnosis is Isoniazid (INH), which is a frequent source of serious and often lethal acute chronic liver damage.Objective: To compare the thirty day hepatoprotective effect of oxyresveratrolformulation and silymarin as an oral supplementary agent for isoniazid induced hepatotoxicity in adult mice.Study design: Experimental studyPlace of study:Department of Pharmacology, Resource lab and Department of Morbid Anatomy and Histopathology, University of Health Sciences, Lahore, Pakistan.Duration of study:Six months from 1st January 2019 to 30th June 2019. Methodology: Adult male mice were divided into five groups with 7 mice in each group. Group I served as a control. Group II, III, IV and V were given isoniazid dissolved in distilled water (100mg body weight per day). Group III was treated with oxyresveratrol 10mg/kg bw/day orally while group IV was given silymarin at 125mg/kg bw/day. Group V was given silymarin 125mg/kg bw/day and oxyresveratrol (10mg/kg bw /day). Liver injury by isoniazid and its protection with oxyresveratrol was assessed by examining liver macroscopically and histological examination. Results: Oxyresveratrol significantly decreased hepatic and portal tract inflammation. Silymarin also decreased the inflammation in both areas significantly but inflammation was better treated by oxyresveratrol. Combination therapy also showed significant decrease in inflammation. Vascular congestion was reduced by oxyresveratrol alone and in combination with silymarin however silymarin alone did not significantly reduce the vascular congestion. Other histological parameters and serum LFTs were same for both drugs and in combination therapy that showed significant improvement and reversal of liver insult. Conclusion: Oxyresveratrol showed hepatoprotective effects against isoniazid induced hepatic damage and showed better protection than silymarin.